{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:01:19Z","timestamp":1771473679388,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1016\/j.yebeh.2003.09.007","type":"journal-article","created":{"date-parts":[[2003,11,24]],"date-time":"2003-11-24T14:09:05Z","timestamp":1069682945000},"page":"702-709","source":"Crossref","is-referenced-by-count":70,"title":["Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial"],"prefix":"10.1016","volume":"4","author":[{"given":"J.A.","family":"Ferrendelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"French","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Leppik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Morrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Herbeuval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Magnus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2003.09.007_BIB1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0733-8619(18)30124-5","article-title":"Seizures and epilepsy in the elderly","volume":"11","author":"Scheuer","year":"1993","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1528-1157.1996.tb00005.x","article-title":"Prevalence of epilepsy in the elderly: the Rotterdam Study","volume":"37","author":"de la Court","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB3","doi-asserted-by":"crossref","unstructured":"American Academy of Neurology. Consensus statements: medical management of epilepsy. Neurology 1998;51(Suppl 4):S39\u201343","DOI":"10.1212\/WNL.51.5_Suppl_4.S39"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB4","unstructured":"Keppra\u00ae prescribing information. Smyrna, GA: UCB Pharma, Inc"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0920-1211(02)00247-4","article-title":"Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy","volume":"53","author":"Ben-Menachem","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00323-0","article-title":"Dose\u2013response effect of levetiracetam 1,000 and 2,000mg\/day in partial epilepsy","volume":"48","author":"Boon","year":"2002","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB9","doi-asserted-by":"crossref","unstructured":"Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3,000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276\u201383.","DOI":"10.1111\/j.1528-1157.2000.tb04605.x"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2,000mg daily and 4,000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-1211(03)00080-9","article-title":"The KEEPER (1) trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study","volume":"54","author":"Morrell","year":"2003","journal-title":"Epilepsy Res."},{"issue":"Suppl 3","key":"10.1016\/j.yebeh.2003.09.007_BIB12","first-page":"A144","article-title":"Levetiracetam in patients aged 65 years: a subset of the KEEPER trial","volume":"60","author":"Ferrendelli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB13","doi-asserted-by":"crossref","unstructured":"International League Against Epilepsy (ILAE). Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389\u201399","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"issue":"Suppl 4","key":"10.1016\/j.yebeh.2003.09.007_BIB14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1528-1157.2001.0420s4040.x","article-title":"Use of levetiracetam in special populations","volume":"42","author":"French","year":"2001","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1016\/j.yebeh.2003.09.007_BIB15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1528-1157.2001.0420s4031.x","article-title":"Efficacy of levetiracetam: a review of three pivotal clinical trials","volume":"42","author":"Privitera","year":"2001","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1016\/j.yebeh.2003.09.007_BIB16","first-page":"142","article-title":"Levetiracetam in elderly patients with epilepsy","volume":"42","author":"Kraemer","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0920-1211(95)00016-4","article-title":"Anticonvulsant therapy in the elderly : a need for placebo controlled trials","volume":"21","author":"Cameron","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0920-1211(99)00039-X","article-title":"Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group","volume":"37","author":"Brodie","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-1211(01)00271-6","article-title":"Lamictal vs. Carbamazepine Study Group. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy","volume":"46","author":"Nieto-Barrera","year":"2001","journal-title":"Epilepsy Res."},{"issue":"Suppl 7","key":"10.1016\/j.yebeh.2003.09.007_BIB20","first-page":"194","article-title":"Evaluation of lamotrigine as adjunctive and monotherapy in elderly patients with epilepsy: a sub-analysis of a large observational study","volume":"43","author":"Kustra","year":"2002","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1016\/j.yebeh.2003.09.007_BIB21","first-page":"165","article-title":"Efficacy and tolerability of topiramate in the elderly population","volume":"43","author":"Mehta","year":"2002","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1016\/j.yebeh.2003.09.007_BIB22","first-page":"217","article-title":"Evaluation of the efficacy and safety of first monotherapy in newly diagnosed elderly patients with partial-seizure epilepsy","volume":"43","author":"Czapinski","year":"2002","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1016\/j.yebeh.2003.09.007_BIB23","first-page":"257","article-title":"Safety and tolerability of oxcarbazepine in elderly patients","volume":"42","author":"Kutluay","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB24","unstructured":"Johnson JE, Pryor FM, Ramsay RE, et al., for the VA Coop Study Group #428. Recruitment of elderly patients in clinical trials. Epilepsia 2001;42(Suppl 7):142. Abstract 2.123"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1086-5802(16)31256-6","article-title":"Pharmacologic management of epilepsy in the elderly","volume":"41","author":"Bourdet","year":"2001","journal-title":"J. Am. Pharm. Assoc. (Wash)"},{"key":"10.1016\/j.yebeh.2003.09.007_BIB26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1535-7597.2001.00013.x","article-title":"Treatment of epilepsy in the elderly","volume":"1","author":"Leppik","year":"2001","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB27","first-page":"8","article-title":"Effects of advancing age on the clinical pharmacology of AEDs","volume":"7","author":"Cloyd","year":"1999","journal-title":"Epilepsy Q."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1345\/aph.1A032","article-title":"Levetiracetam: a different approach to the pharmacotherapy of epilepsy","volume":"36","author":"Welty","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.yebeh.2003.09.007_BIB30","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/j.1552-4604.1997.tb04282.x","article-title":"The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy","volume":"37","author":"Snel","year":"1997","journal-title":"J. Clin. Pharmacol."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505003002749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505003002749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T14:11:33Z","timestamp":1704982293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505003002749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S1525505003002749"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2003.09.007","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}